Being told you have DCIS often brings a confusing mix of messages: it is called cancer, yet many doctors describe it as stage 0, and some say it may never become dangerous. All of that is true at once. Ductal carcinoma in situ is a condition in which abnormal cells are confined inside the milk ducts and have not spread into surrounding breast tissue, and it is now diagnosed in a large number of women each year, mostly through screening mammograms. The central question in DCIS care today is not only how to treat it, but how much treatment each woman truly needs. This guide explains what DCIS is, the standard options, why doctors are debating overtreatment, what recent clinical trials have found, and how research is shaping the choices women will have next.
Newly diagnosed with DCIS?
Studies are testing whether some women can safely have less treatment, along with new ways to prevent invasive breast cancer.
What DCIS is
DCIS stands for ductal carcinoma in situ. "In situ" means in place: the abnormal cells are confined to the lining of the milk ducts and have not broken through into the surrounding breast tissue. Because of that, DCIS cannot spread to lymph nodes or other organs while it remains in situ, which is why it is called stage 0 and is sometimes described as non invasive or pre invasive breast cancer. It usually causes no symptoms and is most often found as tiny calcium deposits on a screening mammogram, then confirmed with a biopsy. The American Cancer Society estimates that about 1 in 5 new breast cancers is DCIS.
Not all DCIS behaves the same way. Pathologists describe it by grade, from low to high, and by whether it is hormone receptor positive. Low grade, hormone receptor positive DCIS tends to grow slowly, while high grade DCIS is more likely to progress if left untreated. Some DCIS would never become invasive cancer in a woman's lifetime, but no test can yet say with certainty which cases will, and that uncertainty is at the heart of how DCIS is treated.
Standard treatment options for DCIS
Lumpectomy. Removing the DCIS with a margin of healthy tissue while keeping the breast; the most common choice.
Radiation after lumpectomy. Often recommended to lower the chance of DCIS or invasive cancer returning in the same breast, though it may be skipped for some women with small, low risk DCIS.
Mastectomy. Removing the breast, sometimes chosen when DCIS is widespread, when there are several areas, or by personal preference.
Hormone therapy. For hormone receptor positive DCIS, tamoxifen or an aromatase inhibitor may be offered for several years to reduce the risk of future breast cancer in either breast.
The outlook after treatment is excellent, and the goal of treatment is mainly to prevent invasive breast cancer from developing later.
Our breast cancer treatment guide covers how these treatments are used in other stages.
The overtreatment debate
Since screening became widespread, DCIS diagnoses have risen sharply, yet the number of women who later develop invasive breast cancer has not fallen to match. That has led many experts to ask whether some women, especially those with low risk DCIS, are being treated with surgery and radiation for a condition that would never have harmed them. Surgery and radiation carry real costs: recovery, changes to the breast, anxiety, and sometimes lasting side effects. The challenge is that, for an individual woman, no one can yet predict reliably whether her DCIS will stay harmless. Clinical trials are the only way to answer that question safely.
What the COMET trial found
The most important recent answer came from the COMET trial, a US study of nearly 1,000 women aged 40 and older with low risk DCIS, meaning grade 1 or 2, hormone receptor positive, and HER2 negative, with no sign of invasive cancer. Women were randomly assigned either to standard surgery, with or without radiation, or to active monitoring with mammograms every six months, with the option of hormone therapy in both groups. After two years, invasive cancer in the same breast was found in 4.2 percent of the active monitoring group and 5.9 percent of the surgery group, showing that active monitoring was not worse at two years. The results, published in JAMA in December 2024, do not mean all DCIS can be watched, and longer follow up is still needed, but they show that for carefully selected women, monitoring may become a reasonable option.
What research is testing now
DCIS is one of the most active areas of early breast cancer research. Current studies are testing shorter and more targeted radiation, ways to safely skip radiation or lymph node surgery for some women, tests that predict which DCIS is likely to progress, and even vaccines designed to train the immune system to stop DCIS from becoming invasive. In the US alone, around 30 studies are currently recruiting women with DCIS. For a woman newly diagnosed, a trial can mean access to an approach not yet standard, along with close monitoring by a research team.
How to find a DCIS or breast cancer study
AllClinicalTrials.com lists breast cancer studies recruiting across the US and Canada, and you can search for DCIS and filter by location. Studies include radiation, surgery, monitoring, and vaccine research for stage 0 breast cancer; see our breast cancer clinical trials page. The application takes about 5 minutes: you answer questions about your diagnosis and pathology results, and if a study near you looks like a match, the research team contacts you. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step. Because many DCIS studies enroll women soon after diagnosis, it helps to look before treatment begins.
Three things to have ready: your biopsy report, including the grade and hormone receptor status of the DCIS, your age, and any treatment you have already had or scheduled.
Common questions
Is DCIS cancer? Yes, it is considered stage 0, non invasive breast cancer: the abnormal cells are confined to the milk ducts and cannot spread while they stay there.
Is DCIS serious?. Treatment aims mainly to prevent invasive breast cancer from developing later, and the risk depends on grade and other features.
Does DCIS always need surgery? Surgery is the standard, but research such as the COMET trial suggests that some women with low risk DCIS may safely choose active monitoring. This is a decision to make with your doctor.
Do I need radiation for DCIS? Radiation after lumpectomy is often recommended to lower the chance of recurrence, but some women with small, low risk DCIS may skip it. Trials are refining who benefits.
Can DCIS come back? It can recur in the same breast, either as DCIS or invasive cancer, which is why follow up mammograms continue after treatment.
Should I take tamoxifen for DCIS? For hormone receptor positive DCIS, hormone therapy may be offered to lower future breast cancer risk. The benefit and side effects are weighed individually.
Can I join a trial with DCIS? Yes. Around 30 studies in the US are recruiting women with DCIS, testing monitoring, radiation, surgery, and vaccine approaches. It helps to look soon after diagnosis.
Do breast cancer trial participants get paid? Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
See breast cancer clinical trials recruiting now
Browse open studies, filter by location, and apply in about 5 minutes: Breast Cancer Clinical Trials.